Melanoma & Skin Cancer | Specialty

The OncLive Melanoma & Skin Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of skin cancers, including melanoma, basal cell carcinoma, and more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in melanoma and other skin cancers.

Immunotherapy in Melanoma: Recognizing an Endocrinopathy

February 8th 2017

Melanoma: Testing for Immunotherapy-Related Hepatotoxicity

February 8th 2017

Immunotherapy-Related Pulmonary Toxicities in Melanoma

February 8th 2017

Managing Gastrointestinal Toxicities in Melanoma

February 8th 2017

Melanoma: Management of Dermatologic Toxicities

February 8th 2017

Overall Toxicities With Immunotherapy in Melanoma

February 8th 2017

Monotherapy Versus Combination Therapy Approaches in Melanoma

February 8th 2017

Melanoma: Speed and Durability of Therapeutic Response

February 8th 2017

BRAF-Mutant Melanoma: Frontline Decisions

February 8th 2017

Immunotherapy in BRAF Wild-Type Melanoma

February 8th 2017

Initial Treatment Approach in Advanced Melanoma: Factors to Consider

February 8th 2017

Explaining Therapeutic Options to Patients With Advanced Melanoma

February 8th 2017

Multidisciplinary Care for Advanced Melanoma at Georgetown University

February 8th 2017

Team Approach to Advanced Melanoma Treatment at MSKCC

February 8th 2017

Complex Scenarios in Advanced Melanoma: Examining Three Patient Cases

February 8th 2017

Despite significant developments on the advanced melanoma treatment front, “many clinical scenarios remain where there is no clear-cut course of action," said Robert H.I. Andtbacka, MD, CM, during a recent OncLive Peer Exchange®.

Pembrolizumab Demonstrates Durable Responses in Rare Subtype of Melanoma

January 31st 2017

Pembrolizumab provided durable activity for previously treated patients with mucosal melanoma, according to data coming out of 3 clinical trials.

Melanoma Case Studies Illustrate Factors in Choosing Targeted Therapies

January 2nd 2017

In recent years, advancements in the treatment of patients with metastatic melanoma have proceeded in 2 areas: targeted therapies and immunotherapies.

Dr. Puzanov on Management of Adverse Events in Melanoma

December 30th 2016

Igor Puzanov, MD, director, Early Phase Clinical Trials Program, chief of Melanoma, coleader, CCSG Experimental Therapeutics Program, professor of Oncology, Department of Medicine, Roswell Park Cancer Institute, discusses ways to manage patients with melanoma who may experience adverse events in response to treatment with immunotherapy.

Dr. Hamid on Patient Selection for Immunotherapy Regimens in Melanoma

December 30th 2016

Omid A. Hamid, MD, chief, Translational Research and Immunotherapy, director, Melanoma Therapeutics, The Angeles Clinic and Research Institute, discusses how to accurately select patients who are likely to have durable and long responses with single-agent immunotherapy versus combination treatment.

Dr. Saenger on Immunotherapy Combinations in Melanoma

December 30th 2016

Yvonne Saenger, MD, director of Melanoma Immunotherapy at Columbia University Medical Center, discusses immunotherapy combinations in melanoma.